NRX Pharmaceuticals (NRXP) Operating Leases (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Operating Leases of $934000.0 for Q1 2026, up 369.35% quarter-over-quarter from $199000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Operating Leases (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Operating Leases for 2 consecutive years, with $934000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $934000.0; the TTM figure through Mar 2026 stood at $934000.0 (changed N/A YoY), while the FY2025 annual figure was $199000.0, changed N/A from the prior year.
Operating Leases rose to $934000.0 in Q1 2026 per NRXP's latest filing, from $199000.0 in the prior quarter.
Across five years, Operating Leases topped out at $934000.0 in Q1 2026 and bottomed at $143000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	140.39 Bn	132.54 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.47 Bn	78.47 Bn	3.93 Bn
3	Argenx Se	65.25 Bn	60.07 Bn	1.37 Bn
4	Moderna	61.79 Bn	56.66 Bn	52.00 Mn
5	BeOne Medicines	42.27 Bn	37.17 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.17 Bn	27.86 Bn	992.69 Mn
7	BioNTech SE	28.61 Bn	10.22 Bn	668.28 Mn
8	Insmed	27.44 Bn	26.28 Bn	358.27 Mn
9	Royalty Pharma	27.30 Bn	26.46 Bn	-
10	NRX Pharmaceuticals	130.83 Mn	104.13 Mn	426,000.00

Download Data